Fluorine-18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement in Patients with Non-Hodgkin Lymphoma and Hodgkin's Disease

Radiologic Clinics of North America

Volumn 45, Issue 4, 2007, Pages 697-709

  Even Sapir, Einat ^a   Lievshitz, Genady ^a   Perry, Chava ^a   Herishanu, Yair ^a   Lerman, Hedva ^a   Metser, Ur ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MEDRONATE TECHNETIUM TC 99M; TRACER;

BONE MARROW; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; GASTROINTESTINAL TRACT; HEAD AND NECK CANCER; HELICOBACTER PYLORI; HODGKIN DISEASE; HUMAN; IMAGING SYSTEM; INCIDENCE; NERVOUS SYSTEM; NONHODGKIN LYMPHOMA; PATHOGENESIS; PELVIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547749027     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2007.05.009     Document Type: Review

References (65)

1. Zucca E., Conconi A., and Cavalli F. Treatment of extranodal lymphomas. Best Pract Res Clin Haematol 15 (2002) 533-547
2. Glass A.G., Karnell L.H., and Menck H.R. The National Cancer Data Base report on non Hodgkin's lymphoma. Cancer 80 (1997) 2311-2320
3. Kostakoglu L., and Goldsmith S.J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?. Eur J Nucl Med 27 (2000) 1564-1578
4. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
5. Groves F.D., Linet M.S., Travis L.B., et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92 (2000) 1240-1251
6. Economopoulos T., Asprou N., Stathakis N., et al. Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics. Leuk Lymphoma 21 (1996) 131-136
7. Cavalli F., Isaacson P.G., Gascoyne R., et al. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 1 (2001) 241-258
8. Maes B., and De Wolf-Peeters C. Marginal zone cell lymphoma-an update on recent advances. Histopathology 40 (2002) 117-126
9. Leonard J.P., Schattner E.J., and Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 13 (2001) 342-347
10. Samaha H., Dumontet C., Ketterer N., et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 12 (1998) 1281-1287
11. Guermazi A., Brice P., de Kerviler E.E., et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics 21 (2001) 161-179
12. Isasi C.R., Lu P., and Blaufox M.D. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
13. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206 (1998) 475-481
14. Israel O., Keidar Z., and Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 34 (2004) 166-179
15. Wiedmann E., Baican B., Hertel A., et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 34 (1999) 545-551
16. Raanani P., Shasha Y., Perry C., et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?. Ann Oncol 17 1 (2006) 117-122
17. Rodriguez M., Ahlstrom H., Sundin A., et al. [18F] FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncol 36 (1997) 577-584
18. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232 (2004) 823-829
19. Bertoni F., and Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 23 (2005) 6415-6420
20. Nakamura S., Aoyagi K., Furuse M., et al. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. Am J Pathol 152 (1998) 1271-1279
21. Hoffmann M., Kletter K., Becherer A., et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64 (2003) 336-340
22. Beal K.P., Yeung H.W., and Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 16 3 (2005) 473-478
23. Natsag J., Tomiyama N., Inoue A., et al. Pulmonary mucosa-associated lymphoid tissue type lymphoma with increased accumulation of fluorine 18-fluorodeoxyglucose on positron emission tomography. J Comput Assist Tomogr 29 (2005) 640-643
24. d'Amore F., Brincker H., Gronbaek K., et al. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol 12 (1994) 1673-1684
25. Salvagno L., Soraru M., Busetto M., et al. Gastric non-Hodgkin's lymphoma: analysis of 252 patients from a multicenter study. Tumori 85 (1999) 113-121
26. Kumar R., Xiu Y., Potenta S., et al. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 45 (2004) 1796-1803
27. Poggi M.M., Cong P.J., Coleman C.N., et al. Low-grade follicular lymphoma of the small intestine. J Clin Gastroenterol 34 (2002) 155-159
28. Metser U., Goor O., Lerman H., et al. PET-CT of extranodal lymphoma. AJR Am J Roentgenol 182 (2004) 1579-1586
29. Wahl R.L. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 45 Suppl 1 (2004) 82S-95S
30. Shirkhoda A., Ros P.R., Farah J., et al. Lymphoma of the solid abdominal viscera. Radiol Clin North Am 28 (1990) 785-799
31. Urba W.J., and Longo D.L. Hodgkin's disease. N Engl J Med 326 (1992) 678-687
32. Munker R., Stengel A., Stabler A., et al. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Cancer 76 8 (1995) 1460-1466
33. Rini J.N., Leonidas J.C., Tomas M.B., et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44 (2003) 1072-1074
34. Metser U., Miller E., Kessler A., et al. Solid splenic masses: evaluation with 18F-FDG PET/CT. J Nucl Med 46 (2005) 52-59
35. Fishman E.K., Kuhlman J.E., and Jones R.J. CT of lymphoma: spectrum of disease. Radiographics 11 (1991) 647-669
36. Kumar R., Xiu Y., Mavi A., et al. FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 30 (2005) 222-230
37. Metser U., Miller E., Lerman H., et al. 18F-fluorodeoxyglucose-PET/CT in the evaluation of adrenal masses. J Nucl Med 47 (2006) 32-37
38. Charnsangavej C. Lymphoma of the genitourinary tract. Radiol Clin North Am 28 (1990) 865-877
39. Kosari F., Daneshbod Y., Parwaresch R., et al. Lymphomas of the female genital tract: a study of 186 cases and review of the literature. Am J Surg Pathol 29 (2005) 1512-1520
40. Lerman H., Metser U., Grisaru D., et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 45 (2005) 266-271
41. Tondini C., Ferreri A.J., Siracusano L., et al. Diffuse large-cell lymphoma of the testis. J Clin Oncol 17 (1999) 2854-2858
42. Fonseca R., Habermann T.M., Colgan J.P., et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 88 (2000) 154-161
43. Tan L.H. Lymphomas involving Waldeyer's ring: placement, paradigms, peculiarities, pitfalls, patterns and postulates. Ann Acad Med Singapore 33 Suppl 4 (2004) 15-26
44. King A.D., Lei K.I., Richards P.S., et al. Non-Hodgkin's lymphoma of the nasopharynx: CT and MR imaging. Clin Radiol 58 (2003) 621-625
45. Morton R.P., Sillars H.A., and Benjamin C.S. Incidence of 'unsuspected' extranodal head and neck lymphoma. Clin Otolaryngol Allied Sci 17 (1992) 373-375
46. Brianzoni E., Rossi G., Ancidei S., et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 32 (2005) 1392-1399
47. Cohen M.S., Arslan N., Dehdashti F., et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130 (2001) 941-946
48. Uno T., Isobe K., Shikama N., Nishikawa A., et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 98 (2003) 865-871
49. Toaff J.S., Metser U., Gottfried M., et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. Invest Radiol 40 (2005) 204-209
50. Ferdinand B., Gupta P., and Kramer E.L. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 24 (2004) 1611-1616
51. Topalovski M., Crisan D., and Mattson J.C. Lymphoma of the breast. A clinicopathologic study of primary and secondary cases. Arch Pathol Lab Med 123 (1999) 1208-1218
52. Kumar R., Xiu Y., Dhurairaj T., et al. F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med 30 (2005) 246-248
53. Pakos E.E., Fotopoulos A.D., and Ioannidis J.P. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46 (2005) 958-963
54. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
55. Kazama T., Faria S.C., Varavithya V., et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 25 (2005) 191-207
56. Sugawara Y., Zasadny K.R., Kison P.V., et al. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med 40 (1999) 1456-1462
57. Burkes B.J., and Gospodarowicz M. Primary non-Hodgkin's lymphoma of bone. Semin Oncol 26 (1999) 270-275
58. Moog F., Kotzerke J., and Reske S.N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40 (1999) 1407-1413
59. Palmedo H., Urbach H., Bender H., et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 33 2 (2006) 164-168
60. Ferreri A.J., Abrey L.E., Blay J.Y., et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, 2002. J Clin Oncol 21 (2003) 2407-2414
61. Hollender A., Kvaloy S., Nome O., et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 13 (2002) 1099-1107
62. Pels H., Vogt I., Klockgether T., et al. Primary non-Hodgkin's lymphoma of the spinal cord. Spine 25 (2000) 2262-2264
63. Metser U., Lerman H., Blank A., et al. Malignant involvement of the spine: assessment by 18F-FDG PET/CT. J Nucl Med 45 (2004) 279-284
64. Kanter P., Zeidman A., Streifler J., et al. PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. Eur J Haematol 74 (2005) 66-69
65. Bokstein F., Goor O., Shihman B., et al. Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case. J Neurooncol 72 (2005) 163-167